Proteome-wide profiling of the MCF10AT breast cancer progression model

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Choong, Lee Yee ^a   Lim, Simin ^a   Chong, Poh Kuan ^a   Wong, Chow Yin ^b   Shah, Nilesh ^a   Lim, Yoon Pin ^a,c,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d BIOINFORMATICS INSTITUTE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AK1 PROTEIN; ATOX1 PROTEIN; CALCIUM BINDING PROTEIN; CELL ADHESION MOLECULE; CYTOSKELETON PROTEIN; HIST1H2BM PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN MCF 10AT; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PROTEOME; TANDEM MASS SPECTROMETRY;

EID: 77955250689     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011030     Document Type: Article

References (47)

1. Olopade OI, Grushko TA, Nanda R, Huo D (2008) Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14: 7988-7999.
2. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, et al. (2001) Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65: 101-110.
3. Strickland LB, Dawson PJ, Santner SJ, Miller FR (2000) Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. Breast Cancer Res Treat 64: 235-240.
4. Heppner GH, Miller FR, Shekhar PM (2000) Nontransgenic models of breast cancer. Breast Cancer Res 2: 331-334.
5. Starcevic SL, Diotte NM, Zukowski KL, Cameron MJ, Novak RF (2003) Oxidative DNA damage and repair in a cell lineage model of human proliferative breast disease (PBD). Toxicol Sci 75: 74-81.
6. Starcevic SL, Elferink C, Novak RF (2001) Progressive resistance to apoptosis in a cell lineage model of human proliferative breast disease. J Natl Cancer Inst 93: 776-782.
7. Tang B, Vu M, Booker T, Santner SJ, Miller FR, et al. (2003) TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112: 1116-1124.
8. Worsham MJ, Pals G, Schouten JP, Miller F, Tiwari N, et al. (2006) High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat 96: 177-186.
9. Rhee DK, Park SH, Jang YK (2008) Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model. Genomics 92: 419-428.
10. Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, et al. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One 5: e9201.
11. Chong PK, Lee H, Kong JW, Loh MC, Wong CH, et al. (2008) Phosphoproteomics, oncogenic signaling and cancer research. Proteomics 8: 4370-4382.
12. Morandell S, Stasyk T, Grosstessner-Hain K, Roitinger E, Mechtler K, et al. (2006) Phosphoproteomics strategies for the functional analysis of signal transduction. Proteomics 6: 4047-4056.
13. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, et al. (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3: 1154-1169.
14. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR (1996) MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148: 313-319.
15. Miller FR (2000) Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia 5: 379-391.
16. Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, et al. (1993) Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 85: 1725-1732.
17. Lim YP, Diong LS, Qi R, Druker BJ, Epstein RJ (2003) Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells. Mol Cancer Ther 2: 1369-1377.
18. Lim YP, Low BC, Lim J, Wong ES, Guy GR (1999) Association of atypical protein kinase C isotypes with the docker protein FRS2 in fibroblast growth factor signaling. J Biol Chem 274: 19025-19034.
19. Lim S, Choong LY, Kuan CP, Yunhao C, Lim YP (2009) Regulation of macrophage inhibitory factor (MIF) by epidermal growth factor receptor (EGFR) in the MCF10AT model of breast cancer progression. J Proteome Res 8: 4062-4076.
20. Elias JE, Gygi SP (2007) Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 4: 207-214.
21. Chen Y, Choong LY, Lin Q, Philp R, Wong CH, et al. (2007) Differential Expression of Novel Tyrosine Kinase Substrates during Breast Cancer Development. Mol Cell Proteomics 6: 2072-2087.
22. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30.
23. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34: D354-357.
24. Ingenuity_Pathways_Analysis [http://www.ingenuity.com/]. Accessed October 16,2009.
25. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, et al. (2003) PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 13: 2129-2141.
26. Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ (2007) Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer 7: 519-530.
27. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS (2006) Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 396: 201-214.
28. Boye K, Maelandsmo GM S100A4 and metastasis: a small actor playing many roles. Am J Pathol 176: 528-535.
29. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, et al. (2006) Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 25: 2328-2338.
30. Ji J, Zhao L, Wang X, Zhou C, Ding F, et al. (2004) Differential expression of S100 gene family in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 130: 480-486.
31. Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN, et al. (2007) Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res 27: 3051-3058.
32. Hendrix MJ, Seftor EA, Chu YW, Trevor KT, Seftor RE (1996) Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 15: 507-525.
33. Liu F, Chen Z, Wang J, Shao X, Cui Z, et al. (2008) Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia 10: 1275-1284.
34. Godfroid E, Geuskens M, Dupressoir T, Parent I, Szpirer C (1991) Cytokeratins are exposed on the outer surface of established human mammary carcinoma cells. J Cell Sci 99 (Pt3): 595-607.
35. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, et al. (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161: 1991-1996.
36. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, et al. (2008) Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 122: 298-304.
37. Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A (2004) Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol 165: 1931-1941.
38. Dressman MA, Baras A, Malinowski R, Alvis LB, Kwon I, et al. (2003) Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 63: 2194-2199.
39. Yamamoto S, Tomita Y, Uruno T, Hoshida Y, Qiu Y, et al. (2005) Increased expression of valosin-containing protein (p97) is correlated with disease recurrence in follicular thyroid cancer. Ann Surg Oncol 12: 925-934.
40. Vandermoere F, El Yazidi-Belkoura I, Slomianny C, Demont Y, Bidaux G, et al. (2006) The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival. J Biol Chem 281: 14307-14313.
41. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482.
42. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006) mTOR, translation initiation and cancer. Oncogene 25: 6416-6422.
43. Young CD, Anderson SM (2008) Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res 10: 202.
44. Itoh S, Kim HW, Nakagawa O, Ozumi K, Lessner SM, et al. (2008) Novel role of antioxidant-1 (Atox1) as a copper-dependent transcription factor involved in cell proliferation. J Biol Chem 283: 9157-9167.
45. Finney L, Vogt S, Fukai T, Glesne D (2008) COPPER AND ANGIOGENESIS: UNRAVELLING A RELATIONSHIP KEY TO CANCER PROGRESSION. Clin Exp Pharmacol Physiol.
46. Goodman VL, Brewer GJ, Merajver SD (2005) Control of copper status for cancer therapy. Curr Cancer Drug Targets 5: 543-549.
47. Silverstein MJ, Buchanan C (2003) Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. Breast 12: 457-471.